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ABSTRACT 
To eva1uate the present situation of the care of hyperg1ycemia， hyper1ipidemia， and b100d 
pressure in type 2 diabetes mellitus， 327 Type 2 diabetic subjects (149 ma1e and 178 fe-
ma1e) were enrolled in the present study. Mean age of participents was 64.2 yr and the 
mean diabetes duration was 13.3 yr. The mean HbA1c va1ue in the who1e popu1ation was 
7.41 土 1.43% (means土 SD)，and 137 subjects (41.9%) had HbA1c be10w 7.0%. The 
mean LDL cho1estero1 and trig1ycerides 1eve1s were 2.75土 0.70and 1. 22 :t O. .67 mmo1/1， 
respective1y， and 193 subjects (59.0%) had LDL cho1estero1 be10w 3.1 and trig1ycerides be-
10w 1. 7 mmol/l. The mean systolic and diasto1ic b100d pressure were 133.0 :t 17.8 and 
71.9 :t 9.5 mmHg， respective1y， and 125 subjects (38.2%) had systo1ic b100d pressure be-
10w 130 and diastolic b100d pressure be10w 85 mmHg. Thus， in the who1e popu1ation， 39 
patients (11.9%) had good contro1 of hyperg1ycemia， hyperlipidemia， and b100d pressure. 
The present resu1ts will serve as a basis for future efforts to improve the qua1ity of dia-
betes care and to reach one of the main goa1s in diabetes care. 
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トリグリセリド{直は2.75土 0.70および1.22 :t 
0.67 mmo1/1であり，そのうち193例 (59.0%)
がI群であった.食事療法群の平均値は2.82土
0.65および1.35 :t 0.71 mmo1/1で，そのうち43
例 (53.8%)がI群であり，経口血糖降下剤治療
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図1.糖尿病患者における血清脂質のコントロール状態
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函2.糖尿病患者における血圧のコントロール状態
食事療法群の平均値は129.1土 18.2および73.0
:t 9.3 mmHgで，そのうち37例 (46.3%)がA
群であり，経口血糖降下剤治療群の平均値は





























ment for Treatment of Hypertension in Diabetes 
および:'AmericanDiabetes Associationならびに
1994年の Nationa1High B100d Pressure Educa-





































リグリセ J)ド値はそれぞれ106.5:t 27，2 mg/dl 
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